Myth: A Stem Cell Treatment Being "Minimally Manipulated" Automatically Makes It Legal Under FDA Rules

What this article covers
- What This Article Covers
- Clinics and patients alike often treat "minimal manipulation" as a magic phrase — if a cell product is only lightly processed (spun in a centrifuge, filtered, rinsed), the thinking goes, it must fall outside FDA regulation and therefore be legal to sell. This article explains why that's wrong on two counts: minimal manipulation is only one of several conditions a cell product must meet to skip FDA premarket approval, and courts have increasingly found that common clinic processing steps — and common uses — fail that test anyway.
- The Myth
- The claim sounds reasonable: FDA's rules are famously described as targeting products that are "more than minimally manipulated," so if a clinic can say its stem cell product is "minimally manipulated," it should be exempt from the agency's drug and biologic approval requirements — no clinical trials, no Biologics License Application, no FDA review needed before treating patients.
- The Reality
- 10, a human cell or tissue-based product (HCT/P) is exempt from FDA premarket review only if it meets all four of a specific set of criteria — not just one. 10).
- What the Evidence Actually Shows
- This isn't theoretical. S.
- Why This Matters
- Patients researching treatments sometimes hear marketing language like "minimally manipulated, same-day procedure" and reasonably assume this is a settled legal safe harbor. It isn't.
What This Article Covers
Clinics and patients alike often treat "minimal manipulation" as a magic phrase — if a cell product is only lightly processed (spun in a centrifuge, filtered, rinsed), the thinking goes, it must fall outside FDA regulation and therefore be legal to sell. This article explains why that's wrong on two counts: minimal manipulation is only one of several conditions a cell product must meet to skip FDA premarket approval, and courts have increasingly found that common clinic processing steps — and common uses — fail that test anyway.
The Myth
The claim sounds reasonable: FDA's rules are famously described as targeting products that are "more than minimally manipulated," so if a clinic can say its stem cell product is "minimally manipulated," it should be exempt from the agency's drug and biologic approval requirements — no clinical trials, no Biologics License Application, no FDA review needed before treating patients.
The Reality
Under 21 CFR § 1271.10, a human cell or tissue-based product (HCT/P) is exempt from FDA premarket review only if it meets all four of a specific set of criteria — not just one. The product must be: (1) minimally manipulated; (2) intended for homologous use only (used to perform the same basic function in the recipient that it performed in the donor); (3) not combined with another article (with narrow exceptions); and (4) either not dependent on the metabolic activity of living cells for its primary function, or, if it is, used only in an autologous setting, a close relative, or for certain reproductive/connective-tissue purposes (Code of Federal Regulations, Title 21 § 1271.10). "Minimally manipulated" and "homologous use" are separate, independently enforced tests — satisfying one says nothing about the other. A clinic can process fat tissue gently and still fail the exemption entirely if it then injects the product into a joint or vein to treat a disease, because that is not the fat's original "homologous" function.
What the Evidence Actually Shows
This isn't theoretical. FDA's own 2017 guidance on minimal manipulation and homologous use explicitly states that processing adipose (fat) tissue into stromal vascular fraction (SVF) — the common enzymatic or mechanical digestion step used at many stem cell clinics — generally constitutes more than minimal manipulation, because it changes the tissue's original relevant characteristics (U.S. Food and Drug Administration, "Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use," 2017). Litigation has reinforced this: in a federal case involving two stem cell clinics, the Ninth Circuit ruled in September 2024 that SVF procedures used by two clinics constituted drug manufacturing requiring FDA approval, rejecting the clinics' minimal-manipulation defense (ISSCR, "Ninth Circuit Reverses Lower Court, Reinforces FDA's Authority to Regulate Unproven Stem Cell Products," 2024). The clinics petitioned the U.S. Supreme Court to review that decision; in October 2025, the Court declined to hear the case, leaving the Ninth Circuit's ruling — and FDA's authority to regulate these products as drugs — intact (AABB, "SCOTUS Declines Stem Cell Case, Upholding FDA Oversight of Cell Therapies," 2025).
Why This Matters
Patients researching treatments sometimes hear marketing language like "minimally manipulated, same-day procedure" and reasonably assume this is a settled legal safe harbor. It isn't. A product can be processed with minimal steps and still require FDA approval if it's used for a purpose different from its original biological role, combined with other substances, or — as the SVF cases show — if courts and FDA disagree with a clinic's own characterization of how much "manipulation" actually occurred. The narrow, genuinely exempt category exists (for example, bone or tendon used for the same structural purpose in the same patient during one surgical procedure), but it is far smaller and more specific than the marketing shorthand suggests.
Bottom Line
"Minimally manipulated" is a real regulatory term, but it is not a shortcut around FDA oversight — it is one of four conditions a product must meet simultaneously, and recent federal court rulings have confirmed that widely marketed procedures, including fat-derived stromal vascular fraction, routinely fail that test or the accompanying homologous-use requirement. Patients should treat the phrase as marketing language to ask follow-up questions about, not as proof that a treatment has cleared any FDA bar.
Key Questions Answered
- Does minimal manipulation alone remove FDA premarket requirements?
- No. Under 21 CFR § 1271.10, an HCT/P must meet all four criteria simultaneously, including homologous use and the conditions governing combination and living-cell metabolic activity.
- What is homologous use?
- It means using the tissue or cell product to perform the same basic function in the recipient that it performed in the donor. It is a separate test from minimal manipulation.
- What did the recent SVF litigation establish?
- The Ninth Circuit's September 2024 ruling treated the clinics' SVF procedures as drug manufacturing requiring FDA approval. The Supreme Court declined review in October 2025, leaving that ruling intact.
Sources
- 21 CFR § 1271.10 – Exception from the requirements of this part, Cornell Law School Legal Information Institute, https://www.law.cornell.edu/cfr/text/21/1271.10
- Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use (Guidance for Industry), U.S. Food and Drug Administration, 2017, https://www.fda.gov/media/89920/download
- Ninth Circuit Reverses Lower Court, Reinforces FDA's Authority to Regulate Unproven Stem Cell Products, International Society for Stem Cell Research (ISSCR), 2024, https://www.isscr.org/isscr-news/ninth-circuit-reverses-lower-court-reinforces-fdas-authority-to-regulate-unproven-stem-cell-products
- Ninth Circuit Upholds FDA's Authority to Regulate Stem Cell Clinic Treatments, The FDA Law Blog (Hyman, Phelps & McNamara), 2024, https://www.thefdalawblog.com/2024/10/ninth-circuit-upholds-fdas-authority-to-regulate-stem-cell-clinic-treatments/
- SCOTUS Declines Stem Cell Case, Upholding FDA Oversight of Cell Therapies, AABB, 2025, https://www.aabb.org/news-resources/news/article/2025/10/15/scotus-declines-stem-cell-case--upholding-fda-oversight-of-cell-therapies
Related Articles
- Fundamentals
What Is Angiogenesis, and Why Does It Matter for Stem Cell Therapy?
New blood vessels don't just show up — they're built, through a process called angiogenesis. Here's what it is, why the body depends on it for healing, and why so much stem cell research is focused on helping it along.
- Fundamentals
Myth: If a Treatment Is Listed on ClinicalTrials.gov, It Must Be Safe and Effective
Seeing a treatment listed on ClinicalTrials.gov can feel like a stamp of approval — but registering a trial costs nothing, requires no proof the treatment works, and isn't vetted by the government for safety or scientific quality.
- Fundamentals
What Are Organoids, and How Are They Grown From Stem Cells?
Organoids are tiny, self-organizing models grown from stem cells. They help study human biology and drug responses but are not complete transplant-ready organs.